JP2020533273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533273A5 JP2020533273A5 JP2020503686A JP2020503686A JP2020533273A5 JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5 JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020503686 A JP2020503686 A JP 2020503686A JP 2020533273 A5 JP2020533273 A5 JP 2020533273A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- tmmp
- amino acid
- mutant
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 231
- 229920001184 polypeptide Polymers 0.000 claims description 219
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 219
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 52
- 230000001105 regulatory effect Effects 0.000 claims description 33
- 230000002519 immonomodulatory effect Effects 0.000 claims description 27
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 25
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 102000000588 Interleukin-2 Human genes 0.000 claims description 13
- 108010002350 Interleukin-2 Proteins 0.000 claims description 13
- 239000000833 heterodimer Substances 0.000 claims description 13
- 210000004899 c-terminal region Anatomy 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102000011786 HLA-A Antigens Human genes 0.000 claims 2
- 108010075704 HLA-A Antigens Proteins 0.000 claims 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims 2
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 2
- 108010051081 dopachrome isomerase Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims 1
- 108700012912 MYCN Proteins 0.000 claims 1
- 101150022024 MYCN gene Proteins 0.000 claims 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 1
- 108700020978 Proto-Oncogene Proteins 0.000 claims 1
- 102000052575 Proto-Oncogene Human genes 0.000 claims 1
- 108010002687 Survivin Proteins 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100032702 Protein jagged-1 Human genes 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- -1 CD86 Proteins 0.000 description 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 1
- 102100034980 ICOS ligand Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- IHUNBGSDBOWDMA-AQFIFDHZSA-N all-trans-acitretin Chemical compound COC1=CC(C)=C(\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O)C(C)=C1C IHUNBGSDBOWDMA-AQFIFDHZSA-N 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555499P | 2017-09-07 | 2017-09-07 | |
| US62/555,499 | 2017-09-07 | ||
| PCT/US2018/049756 WO2019051091A1 (en) | 2017-09-07 | 2018-09-06 | T-LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533273A JP2020533273A (ja) | 2020-11-19 |
| JP2020533273A5 true JP2020533273A5 (enExample) | 2021-10-28 |
Family
ID=65634643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503686A Pending JP2020533273A (ja) | 2017-09-07 | 2018-09-06 | 多量体ｔ細胞調節ポリペプチドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20200148744A1 (enExample) |
| EP (1) | EP3678691A4 (enExample) |
| JP (1) | JP2020533273A (enExample) |
| KR (1) | KR20200040860A (enExample) |
| CN (1) | CN111050793A (enExample) |
| AU (1) | AU2018328280B2 (enExample) |
| BR (1) | BR112020004535A2 (enExample) |
| CA (1) | CA3070484A1 (enExample) |
| EA (1) | EA202090471A1 (enExample) |
| IL (2) | IL297361B2 (enExample) |
| MX (1) | MX2020002596A (enExample) |
| TW (1) | TW201920248A (enExample) |
| WO (1) | WO2019051091A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109475628A (zh) * | 2016-05-18 | 2019-03-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| AU2017379900B2 (en) | 2016-12-22 | 2024-12-05 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| WO2019051127A1 (en) * | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| EP3719033A1 (en) | 2019-04-02 | 2020-10-07 | imusyn GmbH & Co. KG | Stabilized mhc i |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP3986448A4 (en) * | 2019-06-19 | 2023-07-12 | Cue Biopharma, Inc. | MULTIMERIC T-CELL-MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| EP4140495A4 (en) * | 2020-03-18 | 2024-05-01 | GI Innovation, Inc. | Pharmaceutical composition for cancer treatment comprising fusion protein including il-2 protein and cd80 protein and anticancer drug |
| US11897930B2 (en) | 2020-04-28 | 2024-02-13 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| CN111592580A (zh) * | 2020-05-08 | 2020-08-28 | 中国药科大学 | 一种具有免疫检查点ctla-4抑制活性的多肽及其应用 |
| EP4149534A4 (en) | 2020-05-12 | 2024-09-04 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF |
| JP2023525822A (ja) * | 2020-05-12 | 2023-06-19 | エルジー・ケム・リミテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| WO2022015880A2 (en) * | 2020-07-14 | 2022-01-20 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| CN113424794B (zh) * | 2021-04-16 | 2022-07-26 | 安徽农业大学 | 一种优质抗病型地方鸡新品系选育方法 |
| CN119110731A (zh) * | 2022-03-01 | 2024-12-10 | 交联治疗公司 | 作为抗癌剂的免疫细胞功能的atp依赖性激动剂 |
| WO2024231535A1 (en) * | 2023-05-11 | 2024-11-14 | Immudex Aps | Mhc class i molecules |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030007978A1 (en) * | 1997-09-16 | 2003-01-09 | Burrows Gregory G. | Recombinant MHC molecules useful for manipulation of antigen-specific T-cells |
| PT1454138E (pt) * | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| SG11201605632SA (en) * | 2014-01-21 | 2016-08-30 | Einstein Coll Med | Cellular platform for rapid and comprehensive t-cell immunomonitoring |
| SG10202006338UA (en) * | 2014-06-18 | 2020-08-28 | Albert Einstein College Medicine Inc | Syntac polypeptides and uses thereof |
-
2018
- 2018-09-06 IL IL297361A patent/IL297361B2/en unknown
- 2018-09-06 BR BR112020004535-7A patent/BR112020004535A2/pt unknown
- 2018-09-06 EA EA202090471A patent/EA202090471A1/ru unknown
- 2018-09-06 MX MX2020002596A patent/MX2020002596A/es unknown
- 2018-09-06 KR KR1020207008377A patent/KR20200040860A/ko not_active Ceased
- 2018-09-06 TW TW107131332A patent/TW201920248A/zh unknown
- 2018-09-06 JP JP2020503686A patent/JP2020533273A/ja active Pending
- 2018-09-06 CA CA3070484A patent/CA3070484A1/en active Pending
- 2018-09-06 IL IL272085A patent/IL272085B2/en unknown
- 2018-09-06 CN CN201880057027.0A patent/CN111050793A/zh active Pending
- 2018-09-06 EP EP18853880.5A patent/EP3678691A4/en active Pending
- 2018-09-06 WO PCT/US2018/049756 patent/WO2019051091A1/en not_active Ceased
- 2018-09-06 AU AU2018328280A patent/AU2018328280B2/en active Active
-
2020
- 2020-01-21 US US16/747,988 patent/US20200148744A1/en not_active Abandoned
-
2021
- 2021-08-24 US US17/410,453 patent/US20220119483A1/en not_active Abandoned
-
2023
- 2023-01-24 US US18/100,732 patent/US20240025964A1/en not_active Abandoned
-
2024
- 2024-05-02 US US18/653,683 patent/US20250002556A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533273A5 (enExample) | ||
| Korman et al. | The foundations of immune checkpoint blockade and the ipilimumab approval decennial | |
| Touloukian et al. | Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice | |
| Triebel | LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination | |
| KR102436129B1 (ko) | T 세포 수용체 및 이의 용도 | |
| JP6722189B2 (ja) | 単量体Ｆｃドメイン | |
| KR20220066075A (ko) | T-세포 조절 폴리펩타이드 및 이의 사용 방법 | |
| Tutt et al. | T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody | |
| IL272085B (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| US20160199479A1 (en) | T cell receptors | |
| JP2021500855A (ja) | 抗原提示ポリペプチドおよびその使用方法 | |
| Casares et al. | Antigen-specific signaling by a soluble, dimeric peptide/major histocompatibility complex class II/Fc chimera leading to T helper cell type 2 differentiation | |
| JP2018524326A5 (enExample) | ||
| CN115103852A (zh) | Prame tcr受体和其用途 | |
| JP2024512470A (ja) | Ｔ細胞調節ポリペプチド及びその使用方法 | |
| O’Herrin et al. | Antigen-specific blockade of T cells in vivo using dimeric MHC peptide | |
| WO2020132366A4 (en) | T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof | |
| CA3149583A1 (en) | Chimeric proteins in autoimmunity | |
| US20240368246A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JPWO2020243315A5 (enExample) | ||
| Schmittnaegel et al. | A new class of bifunctional major histocompatibility class I antibody fusion molecules to redirect CD8 T cells | |
| CN109562171B (zh) | MHC Ia类开放型构象异构体 | |
| JPWO2020132138A5 (enExample) | ||
| Mittal et al. | An immunotherapeutic CD137 agonist releases eomesodermin from ThPOK repression in CD4 T cells | |
| Gerstmayer et al. | Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein |